These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 21750124)

  • 1. Regulation of angiostatic chemokines driven by IL-12 and IL-27 in human tumors.
    Airoldi I; Ribatti D
    J Leukoc Biol; 2011 Nov; 90(5):875-82. PubMed ID: 21750124
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cancer CXC chemokine networks and tumour angiogenesis.
    Strieter RM; Burdick MD; Mestas J; Gomperts B; Keane MP; Belperio JA
    Eur J Cancer; 2006 Apr; 42(6):768-78. PubMed ID: 16510280
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting tumor micro-environment for design and development of novel anti-angiogenic agents arresting tumor growth.
    Gacche RN; Meshram RJ
    Prog Biophys Mol Biol; 2013 Nov; 113(2):333-54. PubMed ID: 24139944
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The indirect antiangiogenic effect of IL-37 in the tumor microenvironment.
    Mei Y; Zhu Y; Teo HY; Liu Y; Song Y; Lim HY; Binte Hanafi Z; Angeli V; Liu H
    J Leukoc Biol; 2020 May; 107(5):783-796. PubMed ID: 32125036
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CXC and CC chemokines as angiogenic modulators in nonhaematological tumors.
    Santoni M; Bracarda S; Nabissi M; Massari F; Conti A; Bria E; Tortora G; Santoni G; Cascinu S
    Biomed Res Int; 2014; 2014():768758. PubMed ID: 24971349
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Understanding the immunoangiostatic CXC chemokine network.
    Balestrieri ML; Balestrieri A; Mancini FP; Napoli C
    Cardiovasc Res; 2008 May; 78(2):250-6. PubMed ID: 18252760
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Angiostatic activity of the antitumor cytokine interleukin-21.
    Castermans K; Tabruyn SP; Zeng R; van Beijnum JR; Eppolito C; Leonard WJ; Shrikant PA; Griffioen AW
    Blood; 2008 Dec; 112(13):4940-7. PubMed ID: 18515660
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Glucocorticoid-mediated effects on angiogenesis in solid tumors.
    Martens B; Drebert Z
    J Steroid Biochem Mol Biol; 2019 Apr; 188():147-155. PubMed ID: 30654109
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Classical and non-classical proangiogenic factors as a target of antiangiogenic therapy in tumor microenvironment.
    Marech I; Leporini C; Ammendola M; Porcelli M; Gadaleta CD; Russo E; De Sarro G; Ranieri G
    Cancer Lett; 2016 Sep; 380(1):216-26. PubMed ID: 26238184
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Regression of tumor growth and induction of long-term antitumor memory by interleukin 12 electro-gene therapy.
    Li S; Zhang X; Xia X
    J Natl Cancer Inst; 2002 May; 94(10):762-8. PubMed ID: 12011227
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CXCR3, a double-edged sword in tumor progression and angiogenesis.
    Billottet C; Quemener C; Bikfalvi A
    Biochim Biophys Acta; 2013 Dec; 1836(2):287-95. PubMed ID: 23994549
    [TBL] [Abstract][Full Text] [Related]  

  • 12. sFLT01: a novel fusion protein with antiangiogenic activity.
    Bagley RG; Kurtzberg L; Weber W; Nguyen TH; Roth S; Krumbholz R; Yao M; Richards B; Zhang M; Pechan P; Schmid S; Scaria A; Kaplan J; Teicher BA
    Mol Cancer Ther; 2011 Mar; 10(3):404-15. PubMed ID: 21252283
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vesicular trafficking mechanisms in endothelial cells as modulators of the tumor vasculature and targets of antiangiogenic therapies.
    Maes H; Olmeda D; Soengas MS; Agostinis P
    FEBS J; 2016 Jan; 283(1):25-38. PubMed ID: 26443003
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intratumoral myeloid cells regulate responsiveness and resistance to antiangiogenic therapy.
    Rivera LB; Meyronet D; Hervieu V; Frederick MJ; Bergsland E; Bergers G
    Cell Rep; 2015 Apr; 11(4):577-91. PubMed ID: 25892230
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dose-dependent effect of radiation on angiogenic and angiostatic CXC chemokine expression in human endothelial cells.
    Chang CC; Lerman OZ; Thanik VD; Scharf CL; Greives MR; Schneider RJ; Formenti SC; Saadeh PB; Warren SM; Levine JP
    Cytokine; 2009 Dec; 48(3):295-302. PubMed ID: 19782578
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Breast tumor cell soluble factors induce monocytes to produce angiogenic but not angiostatic CXC chemokines.
    Toulza F; Eliaou JF; Pinet V
    Int J Cancer; 2005 Jun; 115(3):429-36. PubMed ID: 15688373
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Metabolic effects of antiangiogenic drugs in tumors: therapeutic implications.
    Quintieri L; Selmy M; Indraccolo S
    Biochem Pharmacol; 2014 May; 89(2):162-70. PubMed ID: 24607274
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The CXC chemokine, monokine induced by interferon-gamma, inhibits non-small cell lung carcinoma tumor growth and metastasis.
    Addison CL; Arenberg DA; Morris SB; Xue YY; Burdick MD; Mulligan MS; Iannettoni MD; Strieter RM
    Hum Gene Ther; 2000 Jan; 11(2):247-61. PubMed ID: 10680839
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chemokines as mediators of neovascularization.
    Keeley EC; Mehrad B; Strieter RM
    Arterioscler Thromb Vasc Biol; 2008 Nov; 28(11):1928-36. PubMed ID: 18757292
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chemokines.
    Hippe A; Homey B; Mueller-Homey A
    Recent Results Cancer Res; 2010; 180():35-50. PubMed ID: 20033377
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.